Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Respiratory Failure

Respiratory Failure

Respiratory Failuer is a serious medical condition characterized by the inability of the lungs to adequately oxygenate the blood or remove carbon dioxide.
It can be caused by a variety of underlying conditions, including pneumonia, COPD, pulmonary edema, and acute respiratory distress syndrome.
Symptoms may include shortness of breath, rapid breathing, and blue discoloration of the skin.
Prompt diagnosis and treatment are crucial to prevent life-threatening complications.
Effective management often involves supplemental oxygen, mechanical ventilation, and addressing the underlying cause.

Most cited protocols related to «Respiratory Failure»

1
Efficacy of BNT162b2 against COVID-19
The first primary end point was the efficacy of BNT162b2 against confirmed Covid-19 with onset at least 7 days after the second dose in participants who had been without serologic or virologic evidence of SARS-CoV-2 infection up to 7 days after the second dose; the second primary end point was efficacy in participants with and participants without evidence of prior infection. Confirmed Covid-19 was defined according to the Food and Drug Administration (FDA) criteria as the presence of at least one of the following symptoms: fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, or vomiting, combined with a respiratory specimen obtained during the symptomatic period or within 4 days before or after it that was positive for SARS-CoV-2 by nucleic acid amplification–based testing, either at the central laboratory or at a local testing facility (using a protocol-defined acceptable test).
Major secondary end points included the efficacy of BNT162b2 against severe Covid-19. Severe Covid-19 is defined by the FDA as confirmed Covid-19 with one of the following additional features: clinical signs at rest that are indicative of severe systemic illness; respiratory failure; evidence of shock; significant acute renal, hepatic, or neurologic dysfunction; admission to an intensive care unit; or death. Details are provided in the protocol.
An explanation of the various denominator values for use in assessing the results of the trial is provided in Table S1 in the Supplementary Appendix, available at NEJM.org. In brief, the safety population includes persons 16 years of age or older; a total of 43,448 participants constituted the population of enrolled persons injected with the vaccine or placebo. The main safety subset as defined by the FDA, with a median of 2 months of follow-up as of October 9, 2020, consisted of 37,706 persons, and the reactogenicity subset consisted of 8183 persons. The modified intention-to-treat (mITT) efficacy population includes all age groups 12 years of age or older (43,355 persons; 100 participants who were 12 to 15 years of age contributed to person-time years but included no cases). The number of persons who could be evaluated for efficacy 7 days after the second dose and who had no evidence of prior infection was 36,523, and the number of persons who could be evaluated 7 days after the second dose with or without evidence of prior infection was 40,137.
Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck RW J.r., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U, & Gruber W.C. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England Journal of Medicine.
Publication 2020
Age Groups Ageusia BNT162B2 Chills Cough COVID 19 Diarrhea Dyspnea Fever Infection Kidney Myalgia Nucleic Acid Amplification Tests Placebos Respiratory Failure Respiratory Rate Safety SARS-CoV-2 Sense of Smell Shock Sore Throat Vaccines
2
Improving Cause of Death Data
Vital registration with medical certification of cause of death is a crucial resource for the GBD cause of death analysis in many countries. Cause of death data obtained using various revisions of the International Classification of Diseases and Injuries (ICD)9 were mapped to the GBD cause list. Many deaths, however, are assigned to causes that cannot be the underlying cause of death (eg, cardiopulmonary failure) or are inadequately specified (eg, injury from undetermined intent). These deaths were reassigned to the most probable underlying causes of death as part of the data processing for GBD. Redistribution algorithms can be divided into three categories: proportionate redistribution, fixed proportion redistribution based on published studies or expert judgment, or statistical algorithms. For GBD 2019, data for 116 million deaths attributed to multiple causes were analysed to produce more empirical redistribution algorithms for sepsis,10 (link) heart failure, pulmonary embolism, acute kidney injury, hepatic failure, acute respiratory failure, pneumonitis, and five intermediate causes (hydrocephalus, toxic encephalopathy, compression of brain, encephalopathy, and cerebral oedema) in the central nervous system. To redistribute unspecified injuries, we used a method similar to that of intermediate cause redistribution, using the pattern of the nature of injury codes in the causal chain where the ICD codes X59 (“exposure to unspecified factor”) and Y34 (“unspecified event, undetermined intent”) and GBD injury causes were the underlying cause of death. These new algorithms led to important changes in the causes to which these intermediate outcomes were redistributed. Additionally, data on deaths from diabetes and stroke lack the detail on subtype in many countries; we ran regressions on vital registration data with at least 50% of deaths coded specifically to type 1 or 2 diabetes and ischaemic, haemorrhagic, or subarachnoid stroke to predict deaths by these subtypes when these were coded to unspecified diabetes or stroke.
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. (2020). Lancet (London, England), 396(10258), 1204-1222.
Full text: Click here
Publication 2020
Brain Central Nervous System Cerebral Edema Cerebrovascular Accident Congestive Heart Failure Diabetes Mellitus Encephalopathies Encephalopathy, Toxic Hemorrhage Hepatic Insufficiency Hydrocephalus Injuries Kidney Injury, Acute Pneumonitis Pulmonary Embolism Respiratory Failure Septicemia Subarachnoid Space
3
Pneumonia Study in Adult Patients
From January 1, 2010, to June 30, 2012, adults 18 years of age or older were enrolled at three hospitals in Chicago (John H. Stroger, Jr., Hospital of Cook County, Northwestern Memorial Hospital, and Rush University Medical Center) and at two in Nashville (University of Tennessee Health Science Center–Saint Thomas Health and Vanderbilt University Medical Center). We sought to enroll all eligible adults; therefore, trained staff screened adults for enrollment at least 18 hours per day, 7 days per week. Written informed consent was obtained from all the patients or their caregivers before enrollment. The study protocol was approved by the institutional review board at each participating institution and at the CDC. Weekly teleconferences, enrollment reports, data audits, and annual study-site visits were conducted to ensure uniform procedures among the study sites. Patients or their caregivers provided demographic and epidemiologic data, and medical charts were abstracted for clinical data. All the authors vouch for the accuracy and completeness of the data and analyses reported and for the fidelity of the study to the protocol. All the authors made the decision to submit the manuscript for publication.
Adults were eligible for enrollment if they were admitted to a study hospital on the basis of a clinical assessment by the treating clinician; resided in the study catchment area (see the Supplementary Appendix, available with the full text of this article at NEJM.org); had evidence of acute infection, defined as reported fever or chills, documented fever or hypothermia, leukocytosis or leukopenia, or new altered mental status; had evidence of an acute respiratory illness, defined as new cough or sputum production, chest pain, dyspnea, tachypnea, abnormal lung examination, or respiratory failure; and had evidence consistent with pneumonia as assessed by means of chest radiography by the clinical team within 48 hours before or after admission.
Patients were excluded if they had been hospitalized recently (<28 days for immunocompetent patients and <90 days for immunosuppressed patients), had been enrolled in the EPIC study within the previous 28 days, were functionally dependent nursing home residents,14 (link) or had a clear alternative diagnosis (see the Supplementary Appendix). Patients were also excluded if they had undergone tracheotomy, if they had a percutaneous endoscopic gastrostomy tube, if they had cystic fibrosis, if they had cancer with neutropenia, if they had received a solid-organ or hematopoietic stem-cell transplant within the previous 90 days, if they had active graft-versus-host disease or bronchiolitis obliterans, or if they had human immunodeficiency virus infection with a CD4 cell count of less than 200 per cubic millimeter.10 (link)
Jain S., Self W.H., Wunderink R.G., Fakhran S., Balk R., Bramley A.M., Reed C., Grijalva C.G., Anderson E.J., Courtney D.M., Chappell J.D., Qi C., Hart E.M., Carroll F., Trabue C., Donnelly H.K., Williams D.J., Zhu Y., Arnold S.R., Ampofo K., Waterer G.W., Levine M., Lindstrom S., Winchell J.M., Katz J.M., Erdman D., Schneider E., Hicks L.A., McCullers J.A., Pavia A.T., Edwards K.M, & Finelli L. (2015). Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. The New England journal of medicine, 373(5), 415-427.
Publication 2015
Adult Bronchiolitis Obliterans CD4+ Cell Counts Chest Pain Chills Cough Cuboid Bone Cystic Fibrosis Diagnosis Dyspnea Endoscopy Ethics Committees, Research Fever Gastrostomy Graft-vs-Host Disease HIV Infections Immunocompetence Infection Leukocytosis Leukopenia Lung Malignant Neoplasms Patients Pneumonia Radiography, Thoracic Respiratory Diaphragm Respiratory Failure Respiratory Rate Sputum Tracheotomy Transplantation, Hematopoietic Stem Cell
4
COVID-19 Severity Categorization Protocol
All cases were divided into four groups: minimal, common, severe, and critical according to whether there were clinical symptoms, severity of pneumonia, respiratory failure, shock, other organ failure, etc., based on the Diagnosis and Treatment Plan of COVID-19 issued by National Health Commission (7th ed.) (in Chinese) [15 ]. (1) Mild type: mild clinical symptoms without pneumonia in imaging; (2) common type: fever, respiratory tract and other symptoms with pneumonia in imaging; (3) severe type: respiratory distress, respiratory rate ≥ 30 times/min; in resting state, oxygen saturation ≤ 93%; PaO2/FiO2 ≤ 300MMHG; (4) critical type: respiratory failure requiring mechanical ventilation, shock and other organ failure requiring ICU monitoring and treatment.
Li K., Fang Y., Li W., Pan C., Qin P., Zhong Y., Liu X., Huang M., Liao Y, & Li S. (2020). CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). European Radiology, 30(8), 4407-4416.
Publication 2020
Chinese COVID 19 Diagnosis Fever Mechanical Ventilation Oxygen Saturation Pneumonia Respiratory Failure Respiratory Rate Respiratory System Shock
5
Pediatric Pneumonia Epidemiology Study
From January 1, 2010 to June 30, 2012, children <18 years old were enrolled in the EPIC study at Le Bonheur Children's Hospital (Memphis, TN), Monroe Carell Jr. Children's Hospital at Vanderbilt (Nashville, TN), and Primary Children's Hospital (Salt Lake City, UT). We sought to enroll all eligible children; thus trained staff screened for enrollment for at least 18 hours each day, 7 days each week. Written informed consent was obtained before enrollment. The study protocol was approved by the institutional review boards at each institution and the CDC. Weekly study teleconferences, required weekly enrollment reports, data audits, and annual site visits were conducted to ensure uniform procedures among sites.
Children were included if they 1) were admitted to one of the three study hospitals;2) resided in one of the 22 counties in the study catchment areas;3) had evidence of acute infection defined as reported fever or chills, documented fever or hypothermia, or leukocytosis or leukopenia; 4) had evidence of an acute respiratory illness defined as new cough or sputum production, chest pain, dyspnea, tachypnea, abnormal lung examination, or respiratory failure; and 5) had chest radiography consistent with pneumonia ≤72 hours of admission.
Children were excluded if they were recently hospitalized (<7 days for immunocompetent, <90 days for immunosuppressed), enrolled in the EPIC study <28 days earlier, resided in an extended care facility, had an alternative respiratory diagnosis, or were newborns who never left the hospital. Children with the following were excluded: tracheostomy, cystic fibrosis, cancer with neutropenia, solid organ or hematopoietic stem cell transplant ≤90 days earlier, active graft-versus-host-disease or bronchiolitis obliterans, or human immunodeficiency virus infection with CD4 cell count <200 cells/mm3 (or CD4%<14%).
Jain S., Williams D.J., Arnold S.R., Ampofo K., Bramley A.M., Reed C., Stockmann C., Anderson E.J., Grijalva C.G., Self W.H., Zhu Y., Patel A., Hymas W., Chappell J.D., Kaufman R.A., Kan J.H., Dansie D., Lenny N., Hillyard D.R., Haynes L.M., Levine M., Lindstrom S., Winchell J.M., Katz J.M., Erdman D., Schneider E., Hicks L.A., Wunderink R.G., Edwards K.M., Pavia A.T., McCullers J.A, & Finelli L. (2015). Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children. The New England journal of medicine, 372(9), 835-845.
Publication 2015
Bronchiolitis Obliterans CD4+ Cell Counts Cells Chest Pain Child Chills Cough Cystic Fibrosis Diagnosis Dyspnea Ethics Committees, Research Fever Grafts HIV Infections Immunocompetence Infant, Newborn Infection Leukocytosis Leukopenia Lung Malignant Neoplasms Pneumonia Radiography, Thoracic Respiratory Failure Respiratory Rate Sodium Chloride, Dietary Sputum Tracheostomy Transplantation, Hematopoietic Stem Cell

Most recents protocols related to «Respiratory Failure»

1
ARISCAT Risk Index for Postoperative Pulmonary Complications
The ARISCAT risk index is used to predict the following: respiratory failure, bronchospasm, respiratory infections, atelectasis, pneumothorax, pleural effusion, and aspiration pneumonitis.9 (link),10 (link) Atelectasis, pneumonia, or pleural effusion were diagnosed by routine clinical examination, chest radiography (chest x-ray or CT), and other relevant investigations. The risk score was classified as: Low risk: < 26, intermediate risk: 26–44, and High risk: ≥45 (Table 1).

Parameters of the ARISCAT Score and Risk Classification

Score ComponentsRisk Score
Age≤50 year0
51–80 year3
>80 year16
Preoperative oxygen saturation≥96%0
91–95%8
≤ 90%24
Respiratory infection in past 1 monthNo0
Yes17
Preoperative hemoglobin < 10g/dlNo0
Yes11
IncisionPeripheral incision0
Upper abdominal incision15
Intrathoracic incision24
Surgery duration<2 hours0
2–3 hours16
>3 hours23
Emergency procedureNo0
Yes8
RiskARISCAT Score
Low< 26 (1.6%)
Medium/Intermediate26–44 (13.3%)
High≥ 45 (42.1%)
Other PPCs have also been reported, such as phrenic dysfunction due to phrenic nerve injury, hoarseness due to recurrent laryngeal nerve injury, difficult extubation, wound infection, and other complications. The management of complications, duration of chest drainage, length of ICU and hospital stay, and patient outcomes (discharge or in-hospital mortality) were also recorded.
Eldaabossi S., Al-Ghoneimy Y., Ghoneim A., Awad A., Mahdi W., Farouk A., Soliman H., Kanany H., Antar A., Gaber Y., Shaarawy A., Nabawy O., Atef M., Nour S.O, & Kabil A. (2023). The ARISCAT Risk Index as a Predictor of Pulmonary Complications After Thoracic Surgeries, Almoosa Specialist Hospital, Saudi Arabia. Journal of Multidisciplinary Healthcare, 16, 625-634.
Publication 2023
Abdomen Aspiration Pneumonia Atelectasis Bronchospasm Hemoglobin Hoarseness Infection Injuries Nipple Discharge Oximetry Oxygen Oxygen Saturation Patient Discharge Patients Phrenic Nerve Physical Examination Pleural Effusion Pneumonia Pneumothorax Radiography, Thoracic Recurrent Laryngeal Nerve Injuries Respiratory Failure Respiratory Tract Infections Tracheal Extubation Wound Infection
2
Examining COVID-19 Lung Pathology
The patient was a 66-year-old man non-smoker with a history of hypertension. SARS-CoV-2 infection was identified by performing a real-time reverse transcriptase (RT)-PCR assay on a nasopharyngeal swab specimen and he was admitted to the hospital on 11 January 2020 with clinical symptoms of cough, fever, myalgia, and mild dyspnea. He developed respiratory failure and received lung transplantation on 25 February 2020. He died on 26 February 2020. More details of this case can be found in the following reference: Analysis of pathological changes in the epithelium in COVID-19 patient airways. Samples from the injured lungs of this patient were embedded in paraffin and sectioned for examination.
Liang S., Bao C., Yang Z., Liu S., Sun Y., Cao W., Wang T., Schwantes-An T.H., Choy J.S., Naidu S., Luo A., Yin W., Black S.M., Wang J., Ran P., Desai A.A, & Tang H. (2023). SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy. Signal Transduction and Targeted Therapy, 8, 108.
Full text: Click here
Publication 2023
Biological Assay Cough COVID 19 Dyspnea Epithelium Fever High Blood Pressures Lung Lung Transplantation Myalgia Nasopharynx Non-Smokers Paraffin Embedding Patients Real-Time Polymerase Chain Reaction Respiratory Failure RNA-Directed DNA Polymerase
3
Barotrauma Incidence in COVID-19 ARDS Patients
Inclusion criteria were all adult (≥ 18 years old) patients with acute hypoxic respiratory failure admitted to the MICU. Exclusion criteria were defined as age <18 years, active pregnancy, incarceration, and incidental PCR positivity without hypoxia. Barotrauma was identified by chart review and confirmed by imaging (CXR or CT scan of the chest). Barotrauma detected post-procedure was excluded from the study.
We defined historical controls as adult patients hospitalized with a primary diagnosis of ARDS (as defined by Berlin criteria) in 2018 and 2019 prior to the onset of the COVID-19 pandemic, admitted to the MICU.
We collected baseline demographic data, comorbid conditions, measures of illness including Sequential Organ Failure Assessment (SOFA) score, and measures of oxygenation and hypoxia including PaO2/FiO2 (P/F) ratio. Support requirements for all patients including use of non-invasive positive pressure ventilation (NIPPV), high flow nasal cannula (HFNC), invasive mechanical ventilation (IMV) and extracorporeal membranous oxygenation (ECMO) were also collected.
Sharma S., Badami V., Rojas E., Sangani R., Chapman K., Avalon C., King A, & Wen S. (2023). High incidence of barotrauma in patients admitted with COVID-19 to ICU and associated mortality in rural Appalachia: An observational study. PLOS ONE, 18(3), e0282735.
Full text: Click here
Publication 2023
Adult Barotrauma Cell Respiration Chest COVID 19 Diagnosis Extracorporeal Membrane Oxygenation Hypoxia Intermittent Positive-Pressure Ventilation Mechanical Ventilation Nasal Cannula Patients Pregnancy Respiratory Distress Syndrome, Acute Respiratory Failure X-Ray Computed Tomography
4
COVID-19 Pneumonia Barotrauma Outcomes
We conducted a single center, retrospective study with historical controls, of patients with acute hypoxic respiratory failure due to COVID-19 pneumonia who were admitted to the XXX Intensive Care Unit (XXX MICU) between September 30, 2020 to December 31, 2020. Institutional review board approval was obtained from WVU IRB (IRB # 2101205408). The electronic medical record (EMR) and imaging studies (chest x-ray and computed tomography scans) were utilized to identify all patients admitted to the MICU with acute hypoxic respiratory failure and a confirmed SARS-CoV-2 polymerase chain reaction (PCR). The primary outcome of the study was rate of barotrauma (pneumothorax, pneumomediastinum, and/or subcutaneous emphysema) and 30-day mortality in those patients with COVID-19 compared to controls. Secondary outcomes of the study included requirement of mechanical ventilation, ICU and hospital LOS. It is important to note that as per the ICU mechanical ventilation protocol all patients were placed on low tidal volume ventilation (4–6 ml/kg/ body weight) and PEEP was set to keep the driving pressures between 14–18 cm of H2O.
Sharma S., Badami V., Rojas E., Sangani R., Chapman K., Avalon C., King A, & Wen S. (2023). High incidence of barotrauma in patients admitted with COVID-19 to ICU and associated mortality in rural Appalachia: An observational study. PLOS ONE, 18(3), e0282735.
Full text: Click here
Publication 2023
Barotrauma Body Weight COVID 19 Hypoxia Mechanical Ventilation Mediastinal Emphysema Patients Pneumonia Pneumothorax Polymerase Chain Reaction Positive End-Expiratory Pressure Radiography, Thoracic Radionuclide Imaging Respiratory Failure SARS-CoV-2 Subcutaneous Emphysema Tidal Volume X-Ray Computed Tomography
5
Bedridden Patients' Sitting Protocol
Twenty patients who were hospitalized and treated in an acute care hospital between May and October 2018 participated in this study. The inclusion criteria were as follows: Being older, requiring nursing care, and having an FIM motor score of <20 points; Having cerebrovascular disease as the leading cause of a bedridden state (at least 6 months have passed since the onset of the disease); Not having chronic respiratory failure or chronic heart failure; Not having a fever (temperature <37.5°C) and having a stable medical condition; Having <14 hours of sitting time in a wheelchair per week[11 (link)]; and; Having rehabilitation prescribed by a physician and having practiced sitting on the edge of a bed for at least 10 minutes with a physical therapist or others, during which the vital signs remained stable.
Yamada Y., Mitani Y., Yamamoto A., Miura K., Yamada K., Oki Y., Oki Y., Maejima Y., Kurumatani Y, & Ishikawa A. (2023). Metabolic and ventilatory changes during postural change from the supine position to the reclining position in bedridden older patients. Medicine, 102(10), e33250.
Full text: Click here
Publication 2023
Congestive Heart Failure Fever nursing Patients Physical Therapist Physicians Rehabilitation Respiratory Failure Signs, Vital Wheelchair

Top products related to «Respiratory Failure»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Stata version 14 by StataCorp
Sourced in United States, Denmark, Austria, United Kingdom, Japan, Canada
Stata version 14 is a software package for data analysis, statistical modeling, and graphics. It provides a comprehensive set of tools for data management, analysis, and reporting. Stata version 14 includes a wide range of statistical techniques, including linear regression, logistic regression, time series analysis, and more. The software is designed to be user-friendly and offers a variety of data visualization options.
3
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
4
Spss version 26 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Austria, Canada, Belgium, Spain
SPSS version 26 is a statistical software package developed by IBM. It is designed to perform advanced statistical analysis, data management, and data visualization tasks. The software provides a wide range of analytical tools and techniques to help users understand and draw insights from their data.
5
Spss version 24 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, China, Spain, Ireland
SPSS version 24 is a statistical software package developed by IBM. It provides a comprehensive set of tools for data analysis, including techniques for descriptive statistics, regression analysis, and predictive modeling. The software is designed to help users interpret data, identify trends, and make informed decisions based on statistical insights.
6
Sas software by SAS Institute
Sourced in United States, Japan, Austria, Germany, United Kingdom, France, Cameroon, Denmark, Israel, Sweden, Belgium, Italy, China, New Zealand, India, Brazil, Canada
SAS software is a comprehensive analytical platform designed for data management, statistical analysis, and business intelligence. It provides a suite of tools and applications for collecting, processing, analyzing, and visualizing data from various sources. SAS software is widely used across industries for its robust data handling capabilities, advanced statistical modeling, and reporting functionalities.
7
Stata version 12 by StataCorp
Sourced in United States, United Kingdom, Denmark, Spain, Austria, Canada, Israel
STATA version 12 is a general-purpose statistical software package developed by StataCorp. It is designed for data analysis, management, and visualization. STATA version 12 provides a wide range of statistical tools and techniques for various applications, including regression analysis, time-series analysis, and survey data analysis.
8
Stata by StataCorp
Sourced in United States, United Kingdom, Denmark, Austria, Belgium, Spain, Australia, Israel
Stata is a general-purpose statistical software package that provides a comprehensive set of tools for data analysis, management, and visualization. It offers a wide range of statistical methods, including regression analysis, time series analysis, and multilevel modeling, among others. Stata is designed to facilitate the analysis of complex data sets and support the entire research process, from data import to report generation.
9
Spss for window by IBM
Sourced in United States, Japan, Germany, United Kingdom, Belgium, Austria
SPSS for Windows is a statistical software package developed by IBM. It is designed to analyze and manipulate data, providing users with tools for data management, analysis, and visualization.
10
Airvo 2 by Fisher & Paykel Healthcare
Sourced in New Zealand
The Airvo 2 is a heated humidifier that delivers warm, humidified respiratory gases to patients who require respiratory support. It is designed to provide high-flow nasal therapy, which helps to improve patient comfort and respiratory function.

More about "Respiratory Failure"

Respiratory Distress is a medical emergency characterized by the lungs' inability to effectively oxygenate the blood or remove carbon dioxide.
This serious condition can stem from various underlying factors, including pneumonia, COPD (Chronic Obstructive Pulmonary Disease), pulmonary edema, and ARDS (Acute Respiratory Distress Syndrome).
Symptoms may manifest as shortness of breath, rapid breathing, and bluish skin discoloration.
Prompt diagnosis and treatment are crucial to prevent life-threatening complications.
Effective management often involves supplemental oxygen, mechanical ventilation, and addressing the root cause.
Researchers can leverage advanced AI-driven platforms like PubCompare.ai to enhance the reproducibility and accuracy of their Respiratory Distress studies.
These tools enable users to locate the most relevant protocols from literature, pre-prints, and patents using powerful search capabilities.
AI-driven comparisons help identify the best protocols and products, optimizing the research process.
By utilizing these cutting-edge solutions, researchers can improve the quality and impact of their Respiratory Distress investigations.
Statistical software like SAS version 9.4, Stata version 14, SAS 9.4, SPSS version 26, SPSS version 24, SAS software, STATA version 12, Stata, and SPSS for Windows can be valuable resources for analyzing data and deriving insights related to Respiratory Distress.
Additionally, medical devices such as the Airvo 2 may play a role in the management and treatment of this condition.
By leveraging a combination of advanced technologies and robust data analysis tools, researchers can enhance their understanding of Respiratory Distress and develop more effective interventions.